BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
@NBCSports Enjoyed the MLB pregame story about #17 Carlos May being the only one to play a game (May 17) with the date on his jersey. Dustin May (#3) of the Cardinals just performed that feat 2 weeks ago.
IVERMECTIN DOSING
A growing number of people are referencing dosing frameworks shared by William Makis for off-label ivermectin use in cancer discussions. Here it is. 👇
Mel Gibson said, “I have three friends. All of them had stage 4 cancer… and now none of them have cancer at all.”
Joe Rogan asked, “What did they take — ivermectin and fenbendazole?”
Mel Gibson nodded, “Yes.”
@dgoold Hi Derrick. I am flying to/from Detroit 4/4 to check off Comerica on quest for 30. Do you have any inside information on whether they plan to play game in the rain or instead opt for day/night doubleheader Sunday?
@knowerofball05@belzpoems@dgoold Why are people on this platform jerks? I had dropped off family close to Arch and I went to park. It was Spring Break for St. Louis schools so there should have been more people.
@knowerofball05@belzpoems@dgoold I said i did not pass a single person. It is real. I saw a couple of people in the distance. As an older woman walking from Arch parking lot to the Arch it was eerie.
@dgoold Sad, but true. I took out of town family downtown on March 17. Walking from LaClede’s Landing to the Arch at 1pm, I did not pass a single person.